Using MRI and machine learning to guide brain surgery for glioblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the application of a computer algorithm that analyzes resting state MRI scans of the brain to predict the response of glioblastoma multiforme tumors to treatment. By utilizing machine learning techniques, the study aims to enhance neuronavigation during neurosurgery, potentially leading to improved surgical outcomes. Participants will undergo pre-operative MRI scans, and their data will be analyzed to develop predictive models for tumor behavior. The study is observational and focuses on patients diagnosed with glioblastoma who are preparing for surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Must have a radiological diagnosis of a lesion in the brain with characteristics consistent with glioblastoma multiforme.
* Must be planning to undergo a pre-operative MRI.
* Must be at least 18 years old.
* Must be able to understand and willing to sign an IRB approved written informed consent document.

Exclusion Criteria:

* Contraindication to MRI.
* Inability to have clinical follow-up (e.g., patient is out of town and will do follow-up elsewhere).

Where it's running

• Washington University School of Medicine
  St Louis, Missouri, United States Recruiting

Study contacts

• Principal investigator: Dimitrios Mathios, M.D. — Washington University School of Medicine
• Study coordinator: Dimitrios Mathios, M.D.
• Email: mathios@wustl.edu
• Phone: 314-747-6146

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

• Adding ruxolitinib to standard radiation and temozolomide for newly diagnosed glioblastoma

  This trial will try whether adding the oral drug ruxolitinib to standard radiation and temozolomide helps adults newly diagnosed with glioblastoma.

  Recruiting at 2 sites Phase 2 Baptist Health South Florida · Miami, Florida and 1 other locations · NCT06991101

• Radiation plus tarlatamab for DLL3-expressing tumors

  This trial will test whether giving tarlatamab together with standard palliative or consolidative radiation is safe for adults with DLL3-expressing or DLL3-prevalent tumors such as melanoma, medullary thyroid cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, and bladder cancer.

  Recruiting at 3 sites Phase 1/2 University of Arizona · Gilbert, Arizona and 2 other locations · NCT06814496

• Using low-intensity magnetic therapy for newly diagnosed glioblastoma patients

  This study is testing whether a low-intensity magnetic therapy device can safely help people who have just been diagnosed with glioblastoma.

  Recruiting at 6 sites BioTex, Inc. · Stuttgart, Baden-Wurttemberg and 5 other locations · NCT06533163

• Evaluating Bevacizumab with Focused Ultrasound for Recurrent Glioblastoma

  This study is testing if adding focused ultrasound to the standard treatment of Bevacizumab can help people with recurrent glioblastoma feel better and live longer.

  Recruiting at 2 sites Phase 3 NaviFUS Corporation · Taipei and 1 other locations · NCT06496971

• Using FET-PET fused with MRI to better map and treat glioblastoma

  This will try using FET-PET combined with contrast MRI to better identify tumor tissue and guide surgery and treatment for adults with a single, newly diagnosed glioblastoma.

  Recruiting Copernicus Memorial Hospital · Lodz, Łódź Voivodeship · NCT06466031

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.